Literature DB >> 18312746

Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease.

Giovanni Tarantino1, Maurizio Marra, Franco Contaldo, Fabrizio Pasanisi.   

Abstract

BACKGROUND: Non-Alcoholic Fatty Liver Disease occurs mainly in severly obese patients and its relationship to Metabolic Syndrome is increasingly recognized. The aim of this study was to determine energy production-utilization by measuring the Basal Metabolic Rate in severely obese patients, characterized by NAFLD, with or without Metabolic Syndrome. Then, the role of systemic inflammation was assessed. PATIENTS AND METHODS: Twenty severly obese men with Metabolic Syndrome were compared with a well-matched cohort of patients without Metabolic Syndrome. All showed hepatic steatosis at UltraSonography. Basal Metabolic Rate was measured by indirect calorimetry using a canopy system and single-frequency bio-impedance analysis. Serum Interleukin-6 and fibrinogen levels were measured as markers of inflammation
RESULTS: Basal Metabolic Rate was higher in severely obese patients with Metabolic Syndrome than in those without it: 2,496+/-358 kcal/d vs 2,126+/-253 kcal/d, P = 0 .001. Laboratory findings of concurrent chronic inflammation were also higher in these patients, i.e., Il6 4.35+/-1.34 pg/ml vs 6.23+/-2.1 pg/ml, P = 0.034; fibrinogenemia 285+/-40 mg/dL vs 376+/-91 mg/dL, P = 0.020; these of of cytonecrosis, i.e., AlaninaminoTransferase, equally behaved 32.3+/-7.9 UI vs 65.7+/-28.2 UI, P < 0.001. Visceral adiposity and arterial hypertension were more frequently detected in patients with Metabolic Syndrome.
CONCLUSION: Increased energy expenditure, observed in morbidly obese patients as a consequence of a systemic, low-grade, inflammatory process, may explain progression from obesity to Metabolic Syndrome, independent of the presence of NAFLD. In this context, increased Basal Metabolic Rate may be a clue of Metabolic Syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312746     DOI: 10.25011/cim.v31i1.3138

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  13 in total

1.  Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis.

Authors:  Fabiola Rabelo; Claudia P M S Oliveira; Joel Faintuch; Daniel F C Mazo; Vicencia M R Lima; Jose Tadeu Stefano; Hermes V Barbeiro; Francisco G Soriano; Venancio A Ferreira Alves; Flair J Carrilho
Journal:  Obes Surg       Date:  2010-07       Impact factor: 4.129

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

3.  Long-Term, Fructose-Induced Metabolic Syndrome-Like Condition Is Associated with Higher Metabolism, Reduced Synaptic Plasticity and Cognitive Impairment in Octodon degus.

Authors:  Daniela S Rivera; Carolina B Lindsay; Juan F Codocedo; Laura E Carreño; Daniel Cabrera; Marco A Arrese; Carlos P Vio; Francisco Bozinovic; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2018-04-13       Impact factor: 5.590

4.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 5.  Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance.

Authors:  Giovanni Tarantino; Silvia Savastano; Annamaria Colao
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

6.  Polysomnographic determinants of nocturnal hypercapnia in patients with sleep apnea.

Authors:  Nattapong Jaimchariyatam; Raed A Dweik; Roop Kaw; Loutfi S Aboussouan
Journal:  J Clin Sleep Med       Date:  2013-03-15       Impact factor: 4.062

7.  Study of beta-cell function (by HOMA model) in metabolic syndrome.

Authors:  M K Garg; M K Dutta; Namita Mahalle
Journal:  Indian J Endocrinol Metab       Date:  2011-07

8.  Circulating levels of sirtuin 4, a potential marker of oxidative metabolism, related to coronary artery disease in obese patients suffering from NAFLD, with normal or slightly increased liver enzymes.

Authors:  Giovanni Tarantino; Carmine Finelli; Franco Scopacasa; Fabrizio Pasanisi; Franco Contaldo; Domenico Capone; Silvia Savastano
Journal:  Oxid Med Cell Longev       Date:  2014-06-17       Impact factor: 6.543

9.  An explorative study of metabolic responses to mental stress and yoga practices in yoga practitioners, non-yoga practitioners and individuals with metabolic syndrome.

Authors:  Anupama Tyagi; Marc Cohen; John Reece; Shirley Telles
Journal:  BMC Complement Altern Med       Date:  2014-11-15       Impact factor: 3.659

10.  Is serum Interleukin-17 associated with early atherosclerosis in obese patients?

Authors:  Giovanni Tarantino; Susan Costantini; Carmine Finelli; Francesca Capone; Eliana Guerriero; Nicolina La Sala; Saverio Gioia; Giuseppe Castello
Journal:  J Transl Med       Date:  2014-08-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.